Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide ...
7don MSN
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Q1 2026 Management View "Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency create better medicines for ...
Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an ...
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results